Active Biotech presents data on paquinimod at EULAR 2014
11 June 2014 - 4:36PM
Active Biotech (NASDAQ OMX NORDIC: ACTI) will
present data related to the drug candidate paquinimod (57-57) for
the treatment of systemic sclerosis, at the scientific conference
"EULAR Annual European Congress of Rheumatology" held in Paris on
June 11-14, 2014.
Active Biotech presentations include:
- (FRI0496) An open-label study to evaluate biomarkers
and safety in systemic sclerosis (SSc) patients treated with
paquinimod (ABR-215757). Hesselstrand R., Distler J.H., Riemekasten
G., Törngren M., Nyhlén H. C., Stenström M., Andersson F., Eriksson
H., Sparre B., Tuvesson H., Distler O. In this study, nine
patients were treated with paquinimod 3 mg/day for eight weeks. The
primary endpoint of the study was changes in disease related
biomarkers. Paquinimod was well tolerated and effects on
biomarkers relevant for SSc were observed during treatment.
- (FRI0516) Paquinimod (ABR-215757), an immunomodulatory
compound, reduces fibrosis in the tight-skin 1 (TSK-1) model for
systemic sclerosis. Stenström M., Nyhlén H. C., Nilsson M.,
Eriksson H., Törngren M., Distler J.H., Distler O., Sparre B.,
Tuvesson H. The purpose of this pre-clinical study was to
investigate the effects of paquinimod in an experimental disease
model for systemic sclerosis. The results show that paquinimod
reduces development of skin fibrosis in this disease model.
For more detailed information, please see www.eular.org.
About paquinimod
Paquinimod is a quinoline compound primarily intended for the
treatment of systemic sclerosis. This rare disease is classified as
an orphan drug indication. In 2011 and 2014, paquinimod was granted
orphan medicinal product status in Europe and US for the indication
systemic sclerosis. The Orphan Medicinal Product Designation is
implemented to promote the development of drugs that may provide
significant benefit to patients suffering from rare diseases
identified as life-threatening or chronically debilitating.
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology
company with focus on autoimmune/inflammatory diseases and cancer.
In pivotal phase is laquinimod (NERVENTRA®), an orally administered
small molecule with unique immunomodulatory properties for the
treatment of multiple sclerosis. Also tasquinimod for the treatment
of prostate cancer, with a unique mode of action, is in pivotal
phase. In addition, laquinimod has concluded Phase II development
for Crohn's and Lupus. The company has two additional projects in
clinical development, ANYARA primarily for the treatment of renal
cell cancer and the orally administered compound paquinimod (57-57)
for systemic sclerosis. Please visit www.activebiotech.com for more
information.
For further information, please contact: Tomas
Leanderson, President & CEO Tel: +46 (0)46 19 20 95 Email:
tomas.leanderson@activebiotech.com
Hans Kolam, CFO Tel: +46 (0)46 19 20 44 E-mail:
hans.kolam@activebiotech.com
Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220
07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11 00
Active Biotech is required under the Financial Instruments
Trading Act to make the information in this press release public.
The information was submitted for publication at 08:30 a.m. CET on
June 11, 2014.
Active Biotech presents data on paquinimod at EULAR 2014
http://hugin.info/1002/R/1791728/616457.pdf
HUG#1791728
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2024 to May 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From May 2023 to May 2024